keyword
https://read.qxmd.com/read/38734568/intrahepatic-cholangiocarcinoma-with-fgfr-alterations-a-series-of-chinese-cases-with-an-emphasis-on-their-clinicopathologic-and-genetic-features
#1
JOURNAL ARTICLE
Jun Zhou, Haoran Yu, Hong Zeng, Qin Shen, Xuewen Wang, Qinxin Xia
Intrahepatic Cholangiocarcinoma (iCCA) with FGFR alterations is relatively rare, and its identification is important in the era of targeted therapy. We collected a large series of FGFR-altered cases in the Chinese population and characterized their clinicopathological and genetic features. Among the 18 FGFR-altered cases out of 260 iCCAs, 10 were males and 8 were females, ranging in age from 35 to 74 years (mean, 57.3 years; median, 58 years). Pathologically, they include 9 cases of large duct (LD, 50 %) and small duct (SD, 50 %) types each...
May 10, 2024: Digestive and Liver Disease
https://read.qxmd.com/read/38730596/diffuse-gliomas-with-fgfr3-tacc3-fusion-morphological-and-molecular-features-and-classification-challenges
#2
REVIEW
Elena Marastoni, Davide Mulone, Valeria Barresi
FGFR3 :: TACC3 fusion is a driver, potentially targetable, genetic alteration identified in approximately 4% of high-grade diffuse gliomas and rare cases with low-grade histology. Herein, we review the genetic and epigenetic features of these tumors and highlight the challenges in their classification and grading. Diffuse gliomas with FGFR3 :: TACC3 fusion display unique histopathological and molecular features, including an oligodendroglioma-like appearance, calcifications, and CD34 extravascular immunoreactivity...
April 25, 2024: Cancers
https://read.qxmd.com/read/38718625/discovery-of-lhq490-as-a-highly-selective-fibroblast-growth-factor-receptor-2-fgfr2-inhibitor
#3
JOURNAL ARTICLE
Huiqiong Li, Ran Ke, Yang Zhou, Shaohua Chang, Jie Wang, Chen Su, Pinglian Wu, Bowen Yang, Zhen Wang, Ke Ding, Dawei Ma
Fibroblast growth factor receptor 2 (FGFR2) represents an appealing therapeutic target for multiple cancers, yet no selective FGFR2 inhibitors have been approved for clinical use to date. Here, we report the discovery of a series of new selective, irreversible FGFR2 inhibitors. The representative compound LHQ490 potently inhibited FGFR2 kinase activity with an IC50 of 5.2 nM, and was >61-, >34-, and >293-fold selective against FGFR1, FGFR3, and FGFR4, respectively. LHQ490 also exhibited high selectivity in a panel of 416 kinases...
May 4, 2024: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/38713442/application-of-plk1-and-hoxa13-gene-expression-levels-in-urine-in-the-diagnosis-of-non-muscle-invasive-bladder-cancer
#4
JOURNAL ARTICLE
Sahar Valizadeh, Sana Taghiyar, Serajedin Vahidi, Omid Abazari, Mahmood Akhavan Tafti, Javad Zavar Reza
Bladder cancer is the most common urinary tract neoplasm, affecting many people annually. Current diagnostic and surveillance methods for bladder cancer are frequently invasive and lack sensitivity and specificity. This study aimed to develop an accurate and non-invasive urine-based gene expression assay, including fibroblast growth factor receptor 3 (FGFR3), homeobox A13 (HOXA13), and polo-like kinase 1 (PLK1), to diagnose non-muscle-invasive bladder cancer (NMIBC) at stages Ta and T1. The samples were acquired from 62 patients with NMIBC, 31 control individuals, and 31 patients with non-cancerous genitourinary tract diseases...
May 7, 2024: Biochemical Genetics
https://read.qxmd.com/read/38710951/pemigatinib-in-previously-treated-solid-tumors-with-activating-fgfr1-fgfr3-alterations-phase-2-fight-207-basket-trial
#5
JOURNAL ARTICLE
Jordi Rodón, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Fibroblast growth factor receptor (FGFR) alterations drive oncogenesis in multiple tumor types. Here we studied pemigatinib, a selective, potent, oral FGFR1-FGFR3 inhibitor, in the phase 2 FIGHT-207 basket study of FGFR-altered advanced solid tumors. Primary end points were objective response rate (ORR) in cohorts A (fusions/rearrangements) and B (activating non-kinase domain mutations). Secondary end points were progression-free survival, duration of response and overall survival in cohorts A and B, and safety...
May 6, 2024: Nature Medicine
https://read.qxmd.com/read/38702915/clinical-utility-of-comprehensive-gene-panel-testing-for-common-and-rare-causes-of-skeletal-dysplasia-and-other-skeletal-disorders-results-from-the-largest-cohort-to-date
#6
JOURNAL ARTICLE
Gretchen MacCarrick, Swaroop Aradhya, Mitch Bailey, Dorna Chu, Abigail Hunt, Emanuela Izzo, Deborah Krakow, William Mackenzie, Sarah Poll, Cathleen Raggio, Renée Shediac, Klane K White, Heather M McLaughlin, Guillermo Seratti
Molecular genetics enables more precise diagnoses of skeletal dysplasia and other skeletal disorders (SDs). We investigated the clinical utility of multigene panel testing for 5011 unrelated individuals with SD in the United States (December 2019-April 2022). Median (range) age was 8 (0-90) years, 70.5% had short stature and/or disproportionate growth, 27.4% had a positive molecular diagnosis (MDx), and 30 individuals received two MDx. Genes most commonly contributing to MDx were FGFR3 (16.9%), ALPL (13.0%), and COL1A1 (10...
May 3, 2024: American Journal of Medical Genetics. Part A
https://read.qxmd.com/read/38701794/retraction-notice-to-precise-editing-of-fgfr3-tacc3-fusion-genes-with-crispr-cas13a-in-glioblastoma
#7
Ye Wu, Weili Jin, Qixue Wang, Junhu Zhou, Yunfei Wang, Yanli Tan, Xiaoteng Cui, Fei Tong, Eryan Yang, Jian Wang, Chunsheng Kang
No abstract text is available yet for this article.
May 2, 2024: Molecular Therapy
https://read.qxmd.com/read/38697030/comprehensive-genomic-characterization-in-ovarian-low-grade-and-chemosensitive-and-chemoresistant-high-grade-serous-carcinomas
#8
JOURNAL ARTICLE
Carolina Jaliffa, Uwe Rogel, Indrani Sen, Gad Singer
INTRODUCTION: Genomic characterization of serous ovarian carcinoma (SOC), which includes low-grade serous carcinoma (LGSC) and high-grade serous carcinoma (HGSC), remains necessary to improve efficacy of platinum-based chemotherapy. The aim was to investigate the genomic variations in these SOC groups, also in relation to chemoresponse. METHODS: 45 samples SOC were retrospectively analyzed by Next Generation Sequencing (NGS) on DNA/RNA extracts from formalin-fixed, paraffin-embedded (FFPE) tumor samples obtained at diagnosis...
May 2, 2024: Oncology
https://read.qxmd.com/read/38696710/patient-with-mediastinal-carcinoma-of-unknown-primary-with-ret-fusion-achieves-durable-response-with-ret-inhibition
#9
JOURNAL ARTICLE
Adam Barsouk, Omar Elghawy, Sara Stone, Aditi Singh
Selective RET inhibitors have shown promise in thyroid cancer (TC) and nonsmall cell lung cancer (NSCLC) harboring RET fusions on next-generation sequencing (NGS), although rarity of the rearrangement has led to limited data for certain tumor types, such as carcinoma of unknown primary. We present a 65-year-old female with no history of malignancy, smoking or radiation exposure, who was found to have an anterior mediastinum malignancy of unknown primary, with metastases to supraclavicular lymph nodes. Core biopsy of the mediastinum revealed poorly differentiated carcinoma, while a biopsy of the thyroid revealed atypia of indeterminate significance (Bethesda III)...
April 29, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38689741/erdafitinib-and-checkpoint-inhibitors-for-first-line-and-second-line-immunotherapy-of-hepatic-gastrointestinal-and-urinary-bladder-carcinomas-recent-concept
#10
EDITORIAL
Mohamed Wishahi
Cancer immunotherapy is administered for first-line, second-line, neoadjuvant, or adjuvant treatment of advanced, metastatic, and recurrent cancer in the liver, gastrointestinal tract, and genitourinary tract, and other solid tumors. Erdafitinib is a fibroblast growth factor receptor (FGFR) inhibitor, and it is an adenosine triphosphate competitive inhibitor of FGFR1, FGFR2, FGFR3, and FGFR4. Immune checkpoint inhibitors are monoclonal antibodies that block programmed cell death protein 1 (PD-1) and its ligand that exert intrinsic antitumor mechanisms...
April 27, 2024: World Journal of Hepatology
https://read.qxmd.com/read/38684670/the-genomic-profiling-of-high-risk-smoldering-myeloma-patients-treated-with-an-intensive-strategy-unveils-potential-markers-of-resistance-and-progression
#11
JOURNAL ARTICLE
A Medina-Herrera, I Vazquez, I Cuenca, J M Rosa-Rosa, B Ariceta, C Jimenez, M Fernandez-Mercado, M J Larrayoz, N C Gutierrez, M Fernandez-Guijarro, V Gonzalez-Calle, P Rodriguez-Otero, A Oriol, L Rosiñol, A Alegre, F Escalante, J De La Rubia, A I Teruel, F De Arriba, M T Hernandez, J Lopez-Jimenez, E M Ocio, N Puig, B Paiva, J J Lahuerta, J Bladé, J F San Miguel, M V Mateos, J Martinez-Lopez, M J Calasanz, R Garcia-Sanz
Smoldering multiple myeloma (SMM) precedes multiple myeloma (MM). The risk of progression of SMM patients is not uniform, thus different progression-risk models have been developed, although they are mainly based on clinical parameters. Recently, genomic predictors of progression have been defined for untreated SMM. However, the usefulness of such markers in the context of clinical trials evaluating upfront treatment in high-risk SMM (HR SMM) has not been explored yet, precluding the identification of baseline genomic alterations leading to drug resistance...
April 29, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38679913/targeted-and-immunotherapy-for-the-management-of-advanced-urothelial-carcinoma-of-the-bladder
#12
JOURNAL ARTICLE
Robert J Cersosimo
DISCLAIMER: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. PURPOSE: The activity of targeted and immunotherapy for the management of advanced bladder cancer is reviewed...
April 29, 2024: American Journal of Health-system Pharmacy: AJHP
https://read.qxmd.com/read/38677772/curcumin-alone-and-combined-with-pi3k-inhibitors-elicits-positive-effects-on-oropharyngeal-cancer-cell-lines-regardless-of-hpv-status
#13
JOURNAL ARTICLE
Monika Lukoceviciute, Mark Zupancic, Ourania N Kostopoulou, Stefan Holzhauser, Tina Dalianis
BACKGROUND/AIM: Human papillomavirus positive (HPV+ ) oropharyngeal squamous cell carcinoma (OPSCC) is rising in incidence. Compared to HPV-negative (HPV- ) OPSCC, HPV+ cases have a better 5-year survival. With its severe side-effects, today's chemoradiotherapy has not improved outcome compared to radiotherapy alone, so new therapies are needed. Mutations in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), fibroblast growth factor receptor 3 (FGFR3) and cell division cycle 27 (CDC27) are found in HPV+ OPSCC, and in vitro targeted therapy combining PI3K and FGFR inhibitors showed synergistic effects...
May 2024: Anticancer Research
https://read.qxmd.com/read/38677755/muscle-invasive-bladder-cancer-with-hydronephrosis-exhibits-a-high-frequency-of-mutations-in-fibroblast-growth-factor-receptor-3-gene
#14
JOURNAL ARTICLE
Kohei Kobatake, Kenichiro Ikeda, Yuki Kohada, Ryo Tasaka, Kenshiro Takemoto, Takafumi Fukushima, Shunsuke Miyamoto, Yohei Sekino, Hiroyuki Kitano, Keisuke Goto, Keisuke Hieda, Akihiro Goriki, Tetsutaro Hayashi, Nobuyuki Hinata
BACKGROUND/AIM: Recent studies have reported conflicting findings regarding the significance of hydronephrosis (HN) in muscle-invasive bladder cancer (MIBC). The molecular characteristics of MIBC with HN are unclear, therefore, we aimed to address the gaps in previous research and elucidate HN's molecular significance in patients with MIBC. MATERIALS AND METHODS: Clinical, genetic, and imaging information on bladder cancer patients enrolled in The Cancer Genome Atlas were obtained from public databases to analyze the association between the presence of hydronephrosis and genetic alterations and molecular subtyping...
May 2024: Anticancer Research
https://read.qxmd.com/read/38672263/exploring-mir-484-regulation-by-polyalthia-longifolia-a-promising-biomarker-and-therapeutic-target-in-cervical-cancer-through-integrated-bioinformatics-and-an-in-vitro-analysis
#15
JOURNAL ARTICLE
Jiaojiao Niu, Yeng Chen, Hwa Chia Chai, Sreenivasan Sasidharan
BACKGROUND: MiR-484, implicated in various carcinomas, holds promise as a prognostic marker, yet its relevance to cervical cancer (CC) remains unclear. Our prior study demonstrated the Polyalthia longifolia downregulation of miR-484, inhibiting HeLa cells. This study investigates miR-484's potential as a biomarker and therapeutic target in CC through integrated bioinformatics and an in vitro analysis. METHODS: MiR-484 levels were analyzed across cancers, including CC, from The Cancer Genome Atlas...
April 19, 2024: Biomedicines
https://read.qxmd.com/read/38662249/case-report-mutation-evolution-in-a-patient-with-tdt-positive-high-grade-b-cell-lymphoma-with-myc-and-bcl2-rearrangements-following-the-treatment-of-concurrent-follicular-lymphoma-and-diffuse-large-b-cell-lymphoma
#16
JOURNAL ARTICLE
Fen Zhang, Yu Chen, Qian Cui, Yan Ge, Yanhui Liu
BACKGROUND: Concurrent follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)was reported in some studies, while the diagnosis of TdT (terminal deoxynucleotydil transferase) positive high grade B cell lymphoma (HGBL) with MYC and BCL2 rearrangements ("double hit") transformed from FL/DLBCL has been rarely reported. Herein, we described the clinical features and mutation profiles of a case diagnosed with TdT positive "double hit" HGBL following the treatment of FL/DLBCL. CASE PRESENTATION: This is a 43-year-old Chinese man who was diagnosed with low grade FL (account for 80%) combined with DLBCL (20%) at a stage of IVB...
April 25, 2024: Discover. Oncology
https://read.qxmd.com/read/38653957/genomic-landscape-of-glioblastoma-without-idh-somatic-mutation-in-42-cases-a-comprehensive-analysis-using-rna-sequencing-data
#17
JOURNAL ARTICLE
Takanari Okamoto, Ryo Mizuta, Yoshinobu Takahashi, Yoshihiro Otani, Eiichi Sasaki, Yoshitsugu Horio, Hiroaki Kuroda, Hirokazu Matsushita, Isao Date, Naoya Hashimoto, Katsuhiro Masago
PURPOSE: Glioblastoma is a malignant brain tumor with a poor prognosis. Genetic mutations associated with this disease are complex are not fully understood and require further elucidation for the development of new treatments. The purpose of this study was to comprehensively analyze genetic mutations in glioblastomas and evaluate the usefulness of RNA sequencing. PATIENTS AND METHODS: We analyzed 42 glioblastoma specimens that were resected in routine clinical practice and found wild-type variants of the IDH1 and IDH2 genes...
April 23, 2024: Journal of Neuro-oncology
https://read.qxmd.com/read/38647531/a-selective-fibroblast-growth-factor-receptor-1-2-protac-degrader-with-antitumor-activity
#18
JOURNAL ARTICLE
Ying Kong, Xinyue Zhao, Zhaofu Wang, Siqi Yuan, Sheng Chen, Shidi Lou, Shichao Ma, Yunfeng Li, Xinghao Wang, Yangfeng Ge, Guobin Li, Hongbing Yang, Mengxi Zhao, Dandan Li, Hailong Zhang, Wenfu Tan, Juan Wang
The aberrant activation of fibroblast growth factor receptor (FGFR) acts as a potent driver of multiple types of human cancers. Despite the development of several conventional small-molecular FGFR inhibitors, their clinical efficacy is largely compromised due to low selectivity and side effects. Here, we report the selective FGFR1/2-targeting proteolysis targeting chimeric (PROTAC), BR-cpd7 that displays significant isoform specificity to FGFR1/2 with DC50 values around 10 nM, while sparing FGFR3. The following mechanistic investigation reveals the reduced FGFR signaling, through which BR-cpd7 induces cell cycle arrest and consequently blocks the proliferation of multiple FGFR1/2-dependent tumor cells...
April 22, 2024: Molecular Cancer Therapeutics
https://read.qxmd.com/read/38638441/fibroblast-growth-factor-receptor-inhibitors-mitigate-the-neuropathogenicity-of-borrelia-burgdorferi-or-its-remnants-ex-vivo
#19
JOURNAL ARTICLE
Geetha Parthasarathy
In previous studies, we showed that fibroblast growth factor receptors (FGFRs) contribute to inflammatory mediator output from primary rhesus microglia in response to live Borrelia burgdorferi . We also demonstrated that non-viable B. burgdorferi can be as pathogenic as live bacteria, if not more so, in both CNS and PNS tissues. In this study we assessed the effect of live and non-viable B. burgdorferi in inducing FGFR expression from rhesus frontal cortex (FC) and dorsal root ganglion (DRG) tissue explants as well as their neuronal/astrocyte localization...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38635549/predisposing-deleterious-variants-in-the-cancer-associated-human-kinases-in-the-global-populations
#20
JOURNAL ARTICLE
Salman Ahmed Khan, Misbah Anwar, Atia Gohar, Moom R Roosan, Daniel C Hoessli, Ambrina Khatoon, Muhammad Shakeel
Human kinases play essential and diverse roles in the cellular activities of maintaining homeostasis and growth. Genetic mutations in the genes encoding the kinases (or phosphotransferases) have been linked with various types of cancers. In this study, we cataloged mutations in 500 kinases genes in >65,000 individuals of global populations from the Human Genetic Diversity Project (HGDP) and ExAC databases, and assessed their potentially deleterious impact by using the in silico tools SIFT, Polyphen2, and CADD...
2024: PloS One
keyword
keyword
119422
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.